- Corporate
Corporate information
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the
SIX Swiss Exchange (SIX:BSLN). Basilea's integrated research and development
operations are currently focused on new antibacterial, antifungal and oncology agents
to fight drug resistance and on the development of dermatology drugs. Basilea's
products are targeted to satisfy high medical and patient needs in the hospital and
specialty care setting. Basilea owns a broad and balanced late-stage product
portfolio that includes novel treatments for resistant bacterial infections, systemic
fungal infections, and severe skin diseases. The company has a fully integrated
R&D organization and has set up commercial organizations in Canada, Denmark,
Germany and the United Kingdom, while it is building sales and marketing
organizations in other countries to commercialize alitretinoin and to co-promote
ceftobiprole, subject to approval.
Pipeline
The company´s diversified portfolio includes two commercialized drugs (alitretinoin,
ceftobiprole), one investigational drug (isavuconazole) in phase III as well as
substantial innovative early-stage programs. Alitretinoin is marketed in the United
Kingdom, Denmark and Germany under the trade name Toctino® and is approved
in Austria, Belgium, Finland, France, Luxemburg, the Netherlands,
Spain and Switzerland. Ceftobiprole is marketed in Canada and in
Switzerland.
- Alitretinoin belongs to the well studied family of retinoids and is targeted at patients with severe chronic hand eczema who do not respond to topical corticosteroids. Alitretinoin is marketed in the United Kingdom, Denmark and Germany and is approved in Austria, Belgium, Finland, France, Luxemburg, the Netherlands, Spain and Switzerland under the trade name Toctino®. Alitretinoin has been recommended for approval in Italy and is under regulatory review in Canada and 15 additional European countries.
- Ceftobiprole is the first approved broad-spectrum anti-MRSA antibiotic belonging to the cephalosporin class. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ for the treatment of complicated skin and skin structure infections (cSSSI), including non-limb threatening diabetic foot infections without concomitant osteomyelitis; and Switzerland (Zevtera™) for the treatment of complicated skin and soft tissue infections including diabetic foot infections (DFI).
- Isavuconazole, a novel broad-spectrum antifungal, is being developed for the treatment of severe invasive fungal infections and has the potential to become the best-in-class azole. The water-soluble compound can be administered intravenously or orally in a once-daily or once-weekly dosing. The investigational drug has received fast track status from the FDA and is in clinical phase III development.
- Preclinical programs: Basilea pursues research programs in lead optimization as well as early stages of discovery. The specific focus is on programs against resistant Gram-negative bacteria and drug-resistance in oncology. Basilea's novel antibiotic BAL30072 has unrivalled activity against some of the most difficult-to-treat multi-resistant Gram-negative bacteria, such as Pseudomonas and Acinetobacter, both in susceptibility tests and in animal models of infection. BAL30072 has the potential to fill the treatment gaps of currently available antibiotics.
History
Basilea was founded in 2000 and went public on the Swiss Exchange in 2004.
© 2010 Basilea Pharmaceutica Ltd.
